Unknown

Dataset Information

0

Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials.


ABSTRACT: Objective: The study aimed to compare the efficacy and safety of androgen deprivation therapy (ADT) with abiraterone or docetaxel versus ADT alone as neoadjuvant therapy in patients with very-high-risk localized prostate cancer. Methods: This was a pooled analysis of two single-center, randomized, controlled, phase II clinical trials (ClinicalTrials.gov: NCT04356430 and NCT04869371) conducted from December 2018 to March 2021. Eligible participants were randomly assigned to the intervention (ADT plus abiraterone or docetaxel) and control (ADT alone) groups at a 2:1 ratio. Efficacy was evaluated by pathological complete response (pCR), minimal residual disease (MRD), and 3-year biochemical progression-free survival (bPFS). Safety was also analyzed. Results: The study included 42 participants in the ADT group, 47 in the ADT plus docetaxel group, and 48 in the ADT plus abiraterone group. A total of 132 (96.4%) participants had very-high-risk prostate cancer, and 108 (78.8%) had locally advanced disease. The ADT plus docetaxel group (28%) and ADT plus abiraterone group (31%) had higher rates of pCR or MRD (p = 0.001 and p < 0.001) compared with the ADT group (2%). The 3-year bPFS was 41.9% (95% CI: 26.6-57.2), 51.1% (95% CI: 36.8-65.4), and 61.2% (95% CI: 45.5-76.9), respectively. Significant difference was found among groups in terms of bPFS (p = 0.037). Conclusion: Compared with ADT alone, neoadjuvant therapy with ADT plus docetaxel or abiraterone could achieve better pathological outcomes (pCR or MRD) for very-high-risk localized prostate cancer. The ADT plus abiraterone group showed longer bPFS than ADT alone. The combination regimens were tolerable.

SUBMITTER: Zhuang J 

PROVIDER: S-EPMC10331422 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials.

Zhuang Junlong J   Wang Yuwen Y   Zhang Shun S   Fu Yao Y   Huang Haifeng H   Lyu Xiaoyu X   Zhang Shiwei S   Marra Giancarlo G   Xu Linfeng L   Qiu Xuefeng X   Guo Hongqian H  

Frontiers in pharmacology 20230626


<b>Objective:</b> The study aimed to compare the efficacy and safety of androgen deprivation therapy (ADT) with abiraterone or docetaxel versus ADT alone as neoadjuvant therapy in patients with very-high-risk localized prostate cancer. <b>Methods:</b> This was a pooled analysis of two single-center, randomized, controlled, phase II clinical trials (<i>ClinicalTrials.gov</i>: NCT04356430 and NCT04869371) conducted from December 2018 to March 2021. Eligible participants were randomly assigned to t  ...[more]

Similar Datasets

| S-EPMC11216961 | biostudies-literature
| S-EPMC4226804 | biostudies-literature
2025-08-27 | GSE224644 | GEO
| S-EPMC5690882 | biostudies-literature
| S-EPMC9972149 | biostudies-literature
| S-EPMC8628395 | biostudies-literature
| S-EPMC5325224 | biostudies-literature
| S-EPMC4012969 | biostudies-literature
| S-EPMC4477786 | biostudies-literature